Výsledky vyhledávání - "J B, Perkins"

Genetic engineering of Bacillus subtilis for the commercial production of riboflavin

Autor: E Zachgo, T Hermann, R Hatch, G A Rufo, J B Perkins, N P Chatterjee, T Erdenberger, V E Williams, N Hannett, A. Sloma, J. Pero, K A Theriault

Publikováno v: Journal of Industrial Microbiology and Biotechnology. 22:8-18

Recombinant DNA engineering was combined with mutant selection and fermentation improvement to develop a strain of Bacillus subtilis that produces commercially attractive levels of riboflavin. The B. subtilis riboflavin production strain contains mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0f76456951f1152f4cf3e550ebd7858
https://doi.org/10.1038/sj.jim.2900587

Zobrazit plný text záznamu

Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer

Autor: K K, Fields, G J, Elfenbein, J B, Perkins, O F, Ballester, S C, Goldstein, J W, Heimenz, R A, Saez, D M, Sullivan, J S, Partyka, L A, Kronish

Publikováno v: Seminars in oncology. 25(2 Suppl 4)

We have explored several novel high-dose combinations in an attempt to increase antitumor activity while decreasing treatment-related toxicity. From October 1989 through June 1997, we performed phase I/II dose-escalation trials exploring novel high-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a01259686b455a2416a96925f9b37c98
https://pubmed.ncbi.nlm.nih.gov/9578055

Zobrazit plný text záznamu

Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery

Autor: O F, Ballester, D P, Agaliotis, J W, Hiemenz, W E, Janssen, K K, Fields, P E, Zorksy, S C, Goldstein, J B, Perkins, G J, Elfenbein

Publikováno v: Bone marrow transplantation. 18(1)

In a phase I-II study, we evaluated toxicities, tolerability, pace of engraftment, and tumor responses to high-dose bulsulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation in patients with hematological malign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1a51655f2ec51d7d9be950f4a7953ab2
https://pubmed.ncbi.nlm.nih.gov/8831989

Zobrazit plný text záznamu

Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer

Autor: J B, Perkins, G J, Effenbein, K K, Fields

Publikováno v: Seminars in oncology. 23(3 Suppl 6)

Dose intensity appears to play a role in the treatment of breast cancer. Although many reports have been published regarding dose intensity using nonmyeloablative doses, little data have been presented in the setting of high-dose chemotherapy and aut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::107756c092ef07e839caee8e2b3990e5
https://pubmed.ncbi.nlm.nih.gov/8677448

Zobrazit plný text záznamu

Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships

Autor: J B, Perkins, K K, Fields, G J, Elfenbein

Publikováno v: Seminars in oncology. 22(3 Suppl 7)

We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer. In a companion phase I/II dose-escalati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5cb5914b2c4722011c6b28fd7808dafc
https://pubmed.ncbi.nlm.nih.gov/7610398

Zobrazit plný text záznamu

High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion

Autor: K K, Fields, G J, Elfenbein, J B, Perkins, W E, Janssen, O F, Ballester, J W, Hiemenz, P E, Zorsky, L E, Kronish, M C, Foody

Publikováno v: Seminars in oncology. 21(5 Suppl 12)

We treated 115 patients in a phase I/II dose-escalation study of ifosfamide/carboplatin/etoposide (ICE) followed by autologous stem cell rescue. Patients treated had a variety of diagnoses, including breast cancer (high-risk stage II disease with eig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1e352c5f6d78518fc9b0aa51da55b459
https://pubmed.ncbi.nlm.nih.gov/7527592

Zobrazit plný text záznamu

Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities

Autor: K K, Fields, G J, Elfenbein, J B, Perkins, J W, Hiemenz, W E, Janssen, P E, Zorsky, O F, Ballester, L E, Kronish, M C, Foody

Publikováno v: Seminars in oncology. 20(5 Suppl 6)

This report describes the results of two phase I/II dose escalation trials for the treatment of metastatic breast cancer. Successive groups of patients with metastatic breast cancer responsive to induction therapy following standard doses of chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88346156a6120582fad0aea7279ad1f7
https://pubmed.ncbi.nlm.nih.gov/8211217

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání